2023, Number 2
Seroprevalence of SARS-CoV-2 and factors related in a population affiliated with a private health insurer in Bogotá, Colombia
Full text
Language: Spanish
References: 19
Page: 243-250
PDF size: 232.83 Kb.
ABSTRACT
Objective: To establish the prevalence of IgG antibodies against SARS-CoV-2 and its relationship with demographic, clinical, and diagnosis variables in a population affiliated with a private health insurer in Bogotá, Colombia.Material and Method:Cross-sectional study, carried out between March and May 2021. The inclusion criteria were adults aged 30 years or more, afebrile, who routinely went to take laboratory samples during the study period –random stratified probability sampling–. A blood sample was obtained to detect IgG antibodies, using the Liaison XLDiasorin platform, with the Liaison® assay reagent, by chemiluminescent immunoassay.
Results: There were included 2009 patients. The estimated seroprevalence for IgG in the study participants was 33.6% (95% CI: 31.6% -35.7%). In the multivariate analysis, the factors associated with seroprevalence were: previous SARS-CoV-2 infection (PR = 2.56, 95% CI: 2.26-2.90), being a health professional (PR = 1.46, 95% CI: 1.14-1.87), have undergone SARS-CoV-2 tests (PR = 1.18, 95% CI: 1.03-1.35) and be between 30 to 49 years old and 50 to 64 years old compared to those over 65 years of age (PR = 1.28, 95% CI: 1.03-1.58; PR = 1.23 95% CI: 1.00-1.53, respectively).
Conclusions: These seroprevalence data are lower than expected for the epidemiological moment of the pandemic in Bogotá; however, it supports the existence of significant heterogeneity in SARS-CoV-2 transmission in our population and indicate that by May 2021 large blocks of the population were still susceptible to infection.
REFERENCES
Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA,Baysson H, De Ridder D, Petrovic D, Schrempft S, Marcus K,Yerly S, Arm Vernez I, Keiser O, Hurst S, Posfay-Barbe KM,Trono D, Pittet D, Gétaz L, Chappuis F, Eckerle I, VuilleumierN, Meyer B, Flahault A, Kaiser L, Guessous I. Seroprevalenceof anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland(SEROCoV-POP): a population-based study. Lancet 2020; 396(10247): 313-319. doi: 10.1016/S0140-6736(20)31304-0.
Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, HernánMA, Pérez-Olmeda M, Sanmartín JL, Fernández-GarcíaA, Cruz I, Fernández de Larrea N, Molina M, Rodríguez-Cabrera F, Martín M, Merino-Amador P, León Paniagua J,Muñoz-Montalvo JF, Blanco F, Yotti R; ENE-COVID StudyGroup. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): anationwide, population-based seroepidemiological study.Lancet 2020; 396 (10250): 535-544. doi: 10.1016/S0140-6736(20)31483-5.
Garay E, Serrano-Coll H, Rivero R, Gastelbondo B, Faccini-Martínez Á, Berrocal J, Pérez A, Badillo M, Martínez-BravoC, Botero Y, Arrieta G, Calderón A, Galeano K, López Y,Miranda J, Guzmán C, Contreras V, Arosemena A, ContrerasH, Brango-Tarra E, Oviedo M, Mattar S. SARS-CoV-2 in eightmunicipalities of the Colombian tropics: high immunity,clinical and sociodemographic outcomes. Trans R Soc TropMed Hyg 2021: trab094. doi: 10.1093/trstmh/trab094.
Mattar S, Alvis-Guzman N, Garay E, Rivero R, García A,Botero Y, Miranda J, Galeano K, de La Hoz F, Martínez C,Arrieta G, Faccini-Martínez ÁA, Guzmán C, Kerguelen H,Moscote M, Contreras H, Contreras V. Severe acute respiratorysyndrome coronavirus 2 seroprevalence amongadults in a tropical city of the Caribbean area, Colombia:Are we much closer to herd immunity than developedcountries? Open Forum Infect Dis 2020; 7 (12): ofaa550.doi: 10.1093/ofid/ofaa550.
Colmenares-Mejía CC, Serrano-Díaz N, Quintero-LesmesDC, Meneses L, Salazar Acosta I, Idrovo ÁJ, Sanabria-Echeverry DY, Cordero-Rebolledo H, Castillo V. Seroprevalenceof SARS-CoV-2 Infection among Occupational Groupsfrom the Bucaramanga Metropolitan Area, Colombia. Int JEnviron Res Public Health 2021; 18 (8): 4172. doi: 10.3390/ijerph18084172.
Yang Y, Wang X, Du RH, Zhang W, Si HR, Zhu Y, Shen XR, LiQ, Li B, Men D, Zhou YN, Wang H, Tong XL, Zhang XE, Shi ZL,Zhou P. Serological investigation of asymptomatic cases ofSARS-CoV-2 infection reveals weak and declining antibodyresponses. Emerg Microbes Infect 2021; 10 (1): 905-912.doi: 10.1080/22221751.2021.1919032.
den Hartog G, Vos ERA, van den Hoogen LL, van Boven M,Schepp RM, Smits G, van Vliet J, Woudstra L, Wijmenga-Monsuur AJ, van Hagen CCE, Sanders EAM, de MelkerHE, van der Klis FRM, van Binnendijk RS. Persistence ofantibodies to SARS-CoV-2 in relation to symptoms in anationwide prospective study. Clin Infect Dis 2021: ciab172.doi: 10.1093/cid/ciab172.